Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acet yl]-pyrrolidine-2(S)-carbonitrile formulation

Details for Australian Patent Application No. 2006257947 (hide)

Owner Novartis AG

Inventors Kowalski, James; Lakshman, Jay Parthiban; Serajuddin, Abu T. M.; Joshi, Yatindra

Agent Davies Collison Cave

Pub. Number AU-B-2006257947

PCT Pub. Number WO2006/135723

Priority 60/690,309 14.06.05 US; 60/689,719 10.06.05 US

Filing date 8 June 2006

Wipo publication date 21 December 2006

Acceptance publication date 10 June 2010

International Classifications

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K 9/22 (2006.01) Medicinal preparations characterised by special physical form - Sustained or differential release type

A61K 9/24 (2006.01) Medicinal preparations characterised by special physical form - Layered or laminated unitary dosage forms

Event Publications

6 December 2007 PCT application entered the National Phase

  PCT publication WO2006/135723 Priority application(s): WO2006/135723

10 June 2010 Application Accepted

  Published as AU-B-2006257947

7 October 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006257948-Electrochemical cell and reference cell with flowing liquid junction

2006257945-Alkylquinoline and alkylquinazoline kinase modulators